13 Aug 2018

ENOUGH IS ENOUGH: MEDICAL GROUPS DEMAND HHS STOP STALLING ON INFORMATION BLOCKING

                Enough is enough. The American Academy of Family Physicians (AAFP) joined 13 other medical associations and healthcare organizations Aug. 9 in telling the federal government it has dragged out the regulation-writing process on an important topic far too long. At issue are the information blocking provisions of the 21st Century

0
09 Aug 2018

BOSTON SCIENTIFIC ANNOUNCES AGREEMENT TO ACQUIRE VENITI AUG. 8

Vici venous stent   Boston Scientific has signed an agreement to acquire Veniti, a privately-held company in Fremont, California, which developed and commercialized the Vici venous stent system for treating venous obstructive disease. Boston Scientific has been an investor in Veniti since 2016 and owned 25 percent of the company. The transaction price for the

0
09 Aug 2018

‘18 AMPUTATION PREVENTION SYMPOSIUM: CARDIOVASCULAR SYSTEMS PRESENTS LIBERTY 360° TWO-YEAR OUTCOMES

Cardiovascular Systems Inc. , medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, presented two-year outcomes from its LIBERTY 360° study in a late-breaking presentation at the 2018 Amputation Prevention Symposium (AMP) in Chicago Aug. 8. The LIBERTY 360° study is designed

0
07 Aug 2018

MICROSOFT IS DEVELOPING A GLASSES-BASED BLOOD PRESSURE MONITOR

            Microsoft is developing new blood pressure monitoring technology called Glabella, which comes equipped on a pair of glasses that passively collects physiological data on the wearer, according to a research paper recently released by the company. The paper was written by Christian Holz, Microsoft Research in Redmond; and  Edward J.

0
07 Aug 2018

VALUE-BASED CARE SUMMIT: LEARN BEST PRACTICES, GET ADVICE FOR TRANSITING TO VALUE-BASED CARE

The third Annual Value-Based Care Summit, which will feature top executives from leading healthcare organizations sharing best practices and real-world advice for succeeding with the transition to value-based care, will be Oct. 17-19 in Boston.                 The Summit will kick-off with a full-day dedicated to revenue cycle management. Keynote speakers

0
04 Aug 2018

SACRAMENTO AREA VASCULAR/VEIN  PRACTICE FOR SALE

    Sebastian Conti, MD, FACS is offering a vascular/vein practice for sale in Sacramento, Calif., area near hospital. Attractive lease, experienced employees, three exam rooms, in office operating room, surgical instruments, VNUS, vascular lab (with tech) EMR >2,000-patient database. Dr. Conti is Northern California’s most experienced vein specialist. With

0
04 Aug 2018

HEALING AT THE MID-LEVEL: TWO MID-LEVEL PRACTITIONERS DISCUSS CHALLENGES, REWARDS, FUTURE OF THEIR PROFESSION

   By Larry Storer Mid-level practitioners in the medical field include occupations of nurse practitioners, nurse midwives, nurse anesthetists, clinical nurse specialists and physician assistants, to name a few. In this article, I asked two mid-level practitioners from American Vein & Vascular Institute to share their thoughts on the occupation,

0
02 Aug 2018

IAC COMPLIMENTARY WEBINAR: IAC VEIN CENTER: ACCREDITATION SIMPLIFIE

  On Thursday, August 23, 2018 at 1 p.m. ET, Laura Humphries, RVT, RPhS, Senior Clinical Specialist will present a live webinar (followed by a Q&A session) entitled IAC Vein Center: Accreditation Simplified.   How to Register Introducing our new and improved IAC Webinar Portal!   To register: Click the Register link below or in

0
01 Aug 2018

FIRST MR THEATER IN U.S. OPENS AT PARRISH HEALTHCARE IN FLORIDA

  Patients at the Parrish Healthcare Center in Titusville, Fla., are the first to have access to enhanced comfort during Magnetic Resonance (MR) exams thanks to the installation of the nation’s first Vantage Titan / Zen Edition 1.5T MR Theater from Canon Medical Systems USA Inc. The new MR theater projects peaceful, virtual reality

0
01 Aug 2018

GE HEALTHCARE, LANTHEUS BEGIN A PHASE 3 CLINICAL TRIAL OF FLURPIRIDAZ TO TREAT CAD

GE Healthcare and Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., have started a second Phase 3 clinical trial of Flurpiridaz 18F (called the AURORA study), an investigational agent being evaluated for the detection of coronary artery disease (CAD), the most common form of heart disease.1 CAD affects an estimated

0